BRAF Gene Mutation clinical trials at UC Irvine

1 research study open to eligible people

Showing trials for

  • IK-595 in RAS- or RAF-altered Advanced Tumors

    open to eligible people ages 18 years and up

    This is a Phase 1, FIH, Dose Escalation and Dose Expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) effects, and preliminary antitumor activity of IK-595, a MEK/RAF molecular glue, administered orally as monotherapy in patients with advanced solid tumors with gene alterations in the RAS- MAPK pathway for whom there are no further treatment options known to confer clinical benefit.

    Orange, California and other locations

Our lead scientists for BRAF Gene Mutation research studies include .

Last updated: